Aratana Therapeutics (PETX) Announces Statistically Significant Data from AT-002 in Cats
Tweet Send to a Friend
Aratana Therapeutics (NASDAQ: PETX) announced the positive results of a pilot field study of AT-002 (capromorelin) in cats. Capromorelin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
